Stargardt Disease Therapeutics Market Growth Forecast from 2020 to 2026 | Worldwide Industry Analysis Focus On business players
SEATTLE, March 17, 2021, (PHARMIWEB) — Global Stargardt Disease Therapeutics Market
The Stargardt disease is an inherited juvenile macular degeneration that causes vision loss. The signs and symptoms of the disease typically appear during late childhood or early adulthood and are known to worsen over time. The most common cause of this disease is the occurrence of mutations in the ABCA4 gene. People suffering from Stargardt disease might notice grey or black color in the middle of eye, or eyes may be more sensitive to bright light. Others may even have symptoms of color blindness. The prevalence for the disease is low, reported at around 1 in 8,000-10,000 people globally, as stated by the National Eye Institute in April 2015. Hence, the disease falls into a rare disease category. Till date, there is no treatment available for this condition, although there are multiple therapies currently in the pipeline.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1314
Robust pipeline for each treatment type that may get regulatory approval over the forecast period is expected to boost the global market growth
The treatment options presently available for the Stargardt disease include drug, gene therapy, and stem cell therapy. For instance, Nightstar Therapeutics expanded its pipeline with gene therapy program for Stargardt Disease treatment in November 2017. In drug category, several companies have received the orphan drug designation (ODD) from the U.S. FDA. In January 2017, Acucela Inc. received orphan drug designation for its leading product emixustat for the treatment of Stargardt disease. In October 2017, Lin BioScience also received orphan n drug designation for its leading product LBS-008 for the treatment of Stargardt Disease. Furthermore, companies such as Astellas Pharma Inc. is working on stem cell therapy for Stargardt disease. With the approval of some of the therapy that are currently in the pipeline, the global Stargardt disease therapeutics market is expected to witness rapid growth over the forecast period.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Quick Buy – Stargardt Disease Therapeutics Market Research Report: https://bit.ly/3ePfkOc
Global Stargardt Disease Therapeutics Market Taxonomy
By Treatment Type:
- Gene Therapy
- Stem Cell Therapy
By Stages of Development:
Global Stargardt Disease Therapeutics Market – Regional Outlook
North America is positioned as the leading market for Stargardt disease, owing to the presence of key market players in the region. For instance, Acucela Inc. and Lin Bioscience, which have received the orphan drug designation for their respective products, are headquartered in the U.S. Other companies such as Astellas Pharma Inc., Copernicus Therapeutics Inc., and Sanofi S.A. are either U.S.-based or have a major presence in the U.S.
Need a discount?
Note: *The discount is offered on the Standard Price of the report.
Request discount for this report @ https://www.coherentmarketinsights.com/insight/request-discount/1314
Europe is expected to hold the second leading position in the global Stargardt disease therapeutics market, as companies like Nightstar therapeutics have shown interest in developing treatment options for the disease in the region. In the Asia Pacific region, Japan is home to companies such as Astellas Pharma Inc. Moreover, major Japan-based pharmaceutical companies are working with small-size Company operating in this area. For instance, Otsuka Pharmaceutical Co., Ltd., a Japan-based company, has continued its collaboration agreement with Acucela Inc., a clinical stage company working on Stargardt disease, since 2008.
Global Stargardt Disease Therapeutics Market – Key Players
The key players operating in the global Stargardt disease therapeutics market include Nemus Bioscience Inc., Acucela Inc., Katairo, Ocata Therapeutics Inc., Sanofi, Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., Copernicus Therapeutics Inc., Grupo Ferrer Internacional SA, Iris Pharma, Ophthotech Corp, and ProQR Therapeutics NV.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/stargardt-disease-therapeutics-market-1314
Table of Content
Global Stargardt Disease Therapeutics Market Research Report
Section 1: Global Stargardt Disease Therapeutics Industry Overview
Section 2: Global Economic Impact on Stargardt Disease Therapeutics Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Stargardt Disease Therapeutics Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Stargardt Disease Therapeutics Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire